Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, Clinical Trials, Market Dynamics, Epidemiology, Companies | DelveInsight

The Lewy Body Dementia (LBD) market across the seven major markets (7MM) was valued at approximately USD 670 million in 2022, with strong growth anticipated through 2034. In 2022, an estimated 11 million dementia cases were recorded across the 7MM, of which ~0.6 million were attributed to Lewy Body Dementia. Rising disease prevalence-driven by aging demographics, enhanced diagnostic capabilities, and increasing awareness-is expected to stimulate market expansion. Companies including EIP Pharma and Cognition Therapeutics are driving therapeutic innovation with candidates such as CT1812, Irsenontrine, Neflamapimod, and LY3154207, with several regulatory milestones anticipated between 2023-2034. These advancements are projected to support a robust CAGR for the LBD therapeutics market throughout the forecast period.

DelveInsight's report, "Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2034," provides a detailed evaluation of LBD, encompassing historical and forecasted epidemiology, current and emerging therapeutic landscape, market share trends, and projected market size across the US, EU4, the UK, and Japan. The analysis highlights treatment algorithms, clinical practices, key market drivers and barriers, unmet needs, and future opportunities in the LBD domain.

To Know in detail about the Lewy Body Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lewy Body Dementia Market Forecast - https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Lewy Body Dementia Market Highlights
• The Lewy Body Dementia market was valued at ~USD 670 million in 2022, expected to grow significantly from 2020-2034.
• June 2025: CervoMed strengthened its development and commercialization strategy for neflamapimod with key leadership appointments.
• July 2025: NKGen Biotech received FDA Expanded Access Program authorization for troculeucel, extending its use to multiple neurodegenerative diseases, including LBD.
• June 2025: Cognition Therapeutics scheduled an end-of-Phase 2 meeting with the FDA to discuss Phase 2 SHINE trial results and the Phase 3 program for zervimesine (CT1812).
• March 2025: Positive interim results from the Phase 2b RewinD-LB extension study of neflamapimod were announced.
• January 2025: C2N Diagnostics partnered with MJFF to advance research into neurodegenerative proteinopathies, including LBD.
• January 2025: Topline data from the SHIMMER study of CT1812 in DLB were presented at ILBDC.
• December 2024: Exploratory Phase 2 SHIMMER results showed significant behavioral, cognitive, and motor improvements with CT1812.
• In 2022, there were 21.4 million prevalent dementia cases in the 7MM, with 12.6 million diagnosed.
• 720,478 individuals in the 7MM were diagnosed with DLB in 2022, projected to rise steadily through 2034.
• The US accounted for 42% of diagnosed DLB cases, with substantial CAGR expected going forward.
• Male prevalence exceeded female prevalence in the US, consistent with global patterns.
• The UK reported the highest DLB prevalence among EU countries in 2022, followed by Germany; Spain recorded the lowest.
• Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc., and others
• Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others
• The Lewy Body Dementia epidemiology based on gender analyzed that through various secondary studies it can be found that LBD more commonly affects males than females
• The Lewy Body Dementia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lewy Body Dementia pipeline products will significantly revolutionize the Lewy Body Dementia market dynamics.

Unlock comprehensive insights into the evolving Lewy Body Dementia market - explore epidemiology trends, key players, emerging therapies, and growth opportunities with DelveInsight's in-depth report : Lewy Body Dementia Treatment Market - https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Lewy Body Dementia Overview
Lewy Body Dementia is a progressive neurodegenerative condition characterized by the accumulation of α-synuclein (Lewy bodies) in the brain. It accounts for 10-15% of all dementia cases and presents with cognitive decline, Parkinsonian motor features, visual hallucinations, REM sleep behavior disorder, and fluctuating cognition. Due to overlapping symptoms with Alzheimer's and Parkinson's disease, misdiagnosis is common. Although no curative therapies exist, symptomatic management through cholinesterase inhibitors, cautious antipsychotic use, and supportive therapies remains the standard. Current research efforts aim to develop disease-modifying treatments.

Lewy Body Dementia Epidemiology Insights
In 2022, the 7MM recorded nearly 21 million dementia cases, with ~52% diagnosed. The US had the largest diagnosed population (~5 million dementia cases), with ~300,000 cases attributed to LBD. Japan followed with ~130,000 diagnosed LBD cases, whereas the UK reported ~44,000. Prevalence was higher in males, and highest among individuals aged 85+. Prevalence across the 7MM is expected to continue rising through 2034 due to aging populations and improved detection.
Lewy Body Dementia Epidemiological segmentation includes:
• Overall Lewy Body Dementia prevalence
• Severity-based prevalence
• Gender distribution
• Diagnosed episodic vs. chronic Lewy Body Dementia cases

Download the report to understand which factors are driving Lewy Body Dementia epidemiology trends @ Lewy Body Dementia Prevalence- https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Lewy Body Dementia Drug Uptake & Pipeline Landscape
Rising healthcare investment and active pipeline development by companies such as Cognition Therapeutics, EIP Pharma, Athira Pharma, Eisai, and Eli Lilly are expected to reshape the LBD treatment landscape.
• E2027: Eisai
• Neflamapimod: EIP Pharma
• K0706: Sun Pharma
• RVT-101: Axovant Sciences Ltd.
• CT1812: Cognition Therapeutics
• K0706: Cephalon
• Irsenontrine: Eisai Inc.
• Neflamapimod: EIP Pharma Inc
• Donepezil: Eisai Co., Ltd.
• ATH-1017: Athira Pharma
• Galantamine: Ortho-McNeil Neurologics, Inc.
• Memantine: H. Lundbeck A/S
• Nelotanserin: Axovant Sciences Ltd.
• DatSCAN: GE Healthcare
• NYX-458: Aptinyx
• N-831(Traneurocin): NeuroActiva, Inc.
• CST-103, CST-107: CuraSen Therapeutics, Inc.
• Pimavanserin: ACADIA Pharmaceuticals Inc.

Discover how pipeline therapies like Neflamapimod (EIP Pharma) and CT1812 (Cognition Therapeutics), along with innovations from key players such as Eisai, Sun Pharma, Axovant, and ACADIA, are shaping the future of Lewy Body Dementia treatment. Access DelveInsight's in-depth market report for strategic insights @ Lewy Body Dementia Medication and Companies - https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Lewy Body Dementia Market Drivers
• Growing prevalence of dementia and aging populations
• Improvements in diagnostics and biomarker technologies
• Advancing pipeline of targeted therapies
• Supportive government and research initiatives
• Increased industry collaboration

Lewy Body Dementia Market Barriers
• Absence of approved disease-modifying therapies
• High attrition rates in neurodegenerative drug trials
• Diagnostic overlap with other neurological disorders
• High cost of emerging therapies
• Limited awareness in developing markets

Lewy Body Dementia Market Report Scope
• Study duration: 2020-2034
• Geography: 7MM - US, EU4, UK, Japan
• Assessment: Market size, epidemiology, pipeline, treatment landscape, reimbursement, unmet needs, and competitive intelligence (SWOT, PESTLE, Porter's Five Forces, BCG Matrix).

To know more about Lewy Body Dementia companies working in the treatment market, visit @ Lewy Body Dementia Clinical Trials and Therapeutic Assessment - https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.